Skip to main content

Table 2 Multivariable logistic regression analyses predicting PrEP experience

From: Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians

 

ALL GENDERSa

N = 140/1405

FEMALEb

n = 24/379

MALEc

n = 111/1009

 

N (%)

AOR

(95% CI)

p-value

N (%)

AOR

(95% CI)

p-value

N (%)

AOR

(95% CI)

p-value

Gender

 Female

24 (6.3)

1

  

–

–

  

–

–

  

 Male

111 (11.0)

1.5

0.9–2.6

0.088

–

–

  

–

–

  

 Transgender

5 (29.4)

3.4

1.0–11.4

0.049

–

–

  

–

–

  

Age (years)

 < 30

12 (16.7)

2.1

1.1–4.2

0.031

    

9 (20.0)

2.3

1.0–5.0

0.048

 30–40

33 (12.3)

1.6

1.0–2.5

0.034

    

25 (14.1)

1.8

1.1–3.0

0.026

 > 40

95 (8.9)

1

      

77 (9.8)

1

  

Enrolling centre

 General hospital

32 (7.3)

1

  

3 (2.5)

1

      

 Research Institute

57 (13.5)

1.9

1.2–3.1

0.006

12 (11.2)

5.5

1.4–21.6

0.014

    

 University Institute

51 (9.4)

1.3

0.8–2.1

0.244

9 (5.9)

2.3

0.6–9.1

0.250

    

Member of HIV associations

 Yes

42 (17.5)

2.2

1.5–3.3

<0.001

6 (10.3)

2.6

0.9–7.6

0.074

33 (18.9)

2.2

1.4–3.4

0.001

Route of HIV transmission

 Heterosexual intercourse

27 (5.7)

1

      

16 (6.5)

1

  

 Homo/Bisexual intercourse

57 (12.2)

1.7

1.0–2.8

0.061

    

49 (11.4)

1.6

0.9–3.0

0.109

 Intravenous Drug Use

34 (14.8)

2.6

1.5–4.5

0.001

    

29 (17.0)

3.1

1.6–5.9

0.001

 Other/unknown

22 (9.2)

1.5

0.8–2.8

0.172

    

17 (10.4)

1.7

0.8–3.5

0.151

Change ART (last 12 months)

 Yes

        

32 (14.5)

1.5

0.9–2.3

0.102

Undetectable HIV RNA

 No

39 (13.7)

1.6

1.1–2.5

0.018

10 (14.5)

4.5

1.8–11.3

0.002

    

Partners’ number (last 3 months)

 No partner

36 (8.1)

   

7 (4.6)

1

      

 Single partner

70 (9.5)

   

13 (6.0)

1.5

0.6–4.0

0.421

    

 Multiple partners

34 (15.0)

   

4 (36.4)

17.5

3.6–84.9

<0.001

    
  1. AOR adjusted odds ratio, CI Confidence Interval, ART antiretroviral therapy, STI sexually transmitted infection
  2. aIncluding Transgender persons (n = 5/17). Significant variables at univariate analysis (p < 0.100): Gender; Age; Enrolling centre; Member of HIV associations; Route of HIV transmission; Undetectable HIV RNA; Partners’ number (last 3 months)
  3. bSignificant variables at univariate analysis (p < 0.100): Age (forced variable); Enrolling centre; Member of HIV associations; Route of HIV transmission; Undetectable HIV RNA; CD4 count/mm3; STI (last 12 mos); Partners’ number (last 3 months)
  4. cSignificant variables at univariate analysis (p < 0.100): Age; Enrolling centre; Member of HIV associations; Route of HIV transmission; Change ART (last 12 months)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us